



Date: November 6, 2018

To

The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: CONSOLIDATION OF SHAREHOLDING IN THE SUBSIDIARY KINEDEX HEALTHCARE PRIVATE LIMITED (KINEDEX/TARGET) BY ERIS LIFESCIENCES LIMITED (COMPANY)

REF.: DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir/Madam,

The Company notifies having executed today a share purchase agreement (Agreement) with Mr. Rakesh Dhuria (one of the founders & promoters of KINEDEX) with the intent of increasing its ownership and control of the said subsidiary i.e. KINEDEX by way of purchase of 12,239 equity shares of face value of Rs. 10/- each (equivalent to 6.71%).

Prior to this transaction, the Company (including its nominees) held 75.48% shareholding in Kinedex. Post completion of this transaction, the total holding of the Company (including its Nominees) shall stand at 82.19% (rounded to two decimal places).

KINEDEX was incorporated in September 18th, 2002 and is engaged, inter alia, in the marketing and selling of pharmaceutical products in India. Kinedex turnover in FY 2017-18 is Rs. 512.29 million. Further Kinedex reported a turnover of Rs. 507.65 million and Rs. 452.65 million in FY 2016-17 and FY 2015-16, respectively. The paid up capital of Kinedex is Rs. 18,25,040/-.

No Regulatory approvals are required for the said acquisition of shares. The investment does not constitute a related party transaction and none of the promoter/ promoter group/ group companies of the Company have interest in KINEDEX.

The Indicative time period for completion of the acquisition is 30 days from the date of execution. The consideration shall be paid through banking channels. The consideration per share is Rs. 8760/-.

For Eris Lifesciences Limited

**Milind Talegaonkar
Company Secretary & Compliance Officer**

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: April, 6 2019

To

The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: CONSOLIDATION OF SHAREHOLDING IN THE SUBSIDIARY KINEDEX HEALTHCARE PRIVATE LIMITED (KINEDEX/TARGET) BY ERIS LIFESCIENCES LIMITED (COMPANY)

REF.: DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir/Madam,

The Company notifies having executed today a share purchase agreement (Agreement) with Mr. Rajesh Dhuria (one of the founders & promoters of KINEDEX) with the intent to have full ownership and control of the said subsidiary (KINEDEX) and to make KINEDEX a wholly-owned subsidiary i.e. by way of purchase of 32,507 equity shares of face value of Rs. 10/- each (equivalent to ~17.81%).

Prior to this transaction, the Company (including its nominees) held ~82.19% shareholding in KINEDEX. Post completion of this transaction, the total holding of the Company (including its Nominees) shall stand at 100%.

KINEDEX was incorporated on September 18th, 2002 and is engaged, inter alia, in the marketing and selling of pharmaceutical products in India. KINEDEX turnover in FY 2017-18 was Rs. 512.29 million. Further KINEDEX reported a turnover of Rs. 507.65 million and Rs. 452.65 million in FY 2016-17 and FY 2015-16, respectively. The paid up capital of KINEDEX is Rs. 18,25,040/-.

No Regulatory approvals are required for the said acquisition of shares. The investment does not constitute a related party transaction and none of the promoter/ promoter group/ group companies of the Company have interest in KINEDEX.

The Indicative time period for completion of the transaction is 30 days from the date of execution. The consideration shall be paid through banking channels. The consideration per share is Rs. 6575/-.

For Eris Lifesciences Limited

**Milind Talegaonkar
Company Secretary & Compliance Officer**

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867